Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CRBP

CRBP - Corbus Pharmaceuticals Holdings Inc Stock Price, Fair Value and News

$9.40-0.19 (-1.98%)
Market Closed

36/100

CRBP

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

36/100

CRBP

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CRBP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CRBP Price Action

Last 7 days

17.3%

Last 30 days

23.4%

Last 90 days

-3.1%

Trailing 12 Months

46.4%

CRBP RSI Chart

CRBP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CRBP Valuation

Market Cap

166.7M

Price/Earnings (Trailing)

-2.12

Price/Sales (Trailing)

30.15

Price/Free Cashflow

-2.58

CRBP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CRBP Fundamentals

CRBP Revenue

Revenue (TTM)

5.5M

CRBP Earnings

Earnings (TTM)

-78.5M

Earnings Growth (Yr)

-115.69%

Earnings Growth (Qtr)

11.94%

CRBP Profitability

Return on Equity

-53.24%

Return on Assets

-46.69%

Free Cashflow Yield

-38.69%

CRBP Investor Care

Shares Dilution (1Y)

45.00%

Diluted EPS (TTM)

-5.9

CRBP Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20257.0M6.7M5.9M5.5M
20242.8M4.0M5.1M6.3M
20230001.6M
20212.8M2.7M1.5M881.7K
202036.0M7.2M5.9M3.9M
20195.8M34.0M35.5M36.1M
20182.1M2.6M2.9M4.8M
20172.8M2.8M2.8M2.4M
2016964.1K1.3M1.6M1.9M
2015000648.4K
Get all data in R, Python etc through our Historical Stock Data APIs

About Corbus Pharmaceuticals Holdings Inc

CRBP
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
 CEO
 WEBSITEcorbuspharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES33

Corbus Pharmaceuticals Holdings Inc Frequently Asked Questions

CRBP is the stock ticker symbol of Corbus Pharmaceuticals Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Corbus Pharmaceuticals Holdings Inc is 166.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, CRBP's PE ratio (Price to Earnings) is -2.12 and Price to Sales (PS) ratio is 30.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRBP PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Corbus Pharmaceuticals Holdings Inc has provided -0.162 (multiply by 100 for percentage) rate of return.